DIVISTA chromium picolinate capsule

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

CHROMIUM PICOLINATE (UNII: S71T8B8Z6P) (CHROMIC CATION - UNII:X1N4508KF1)

Available from:

US Pharmaceutical Corporation

INN (International Name):

CHROMIUM PICOLINATE

Composition:

CHROMIUM PICOLINATE 1000 ug

Prescription type:

PRESCRIPTION DRUG

Authorization status:

unapproved drug other

Summary of Product characteristics

DIVISTA - CHROMIUM PICOLINATE CAPSULE
US PHARMACEUTICAL CORPORATION
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
SEE ALL PRESCRIBING INFORMATION FOR DIVISTA
DivistaTM is specially designed as a once a day nutritional adjuvant
to the current standard of care for
patients with, or at risk of developing type 2 diabetes mellitus
(T2DM). DivistaTM provides a method
for reducing hyperglycemia and stabilizing the level of serum
cholesterol.
DivistaTM is unique in that it utilizes two patented nutritional
ingredients, Chromax® (chromium
picolinate) and Diachrome® (chromium picolinate and biotin), along
with Omega-3 fatty acids to aid in
enhancing insulin sensitivity and improve blood sugar metabolism,
while promoting healthy lipids and
supporting healthy triglyceride levels.
Chromium: is an essential trace mineral required by the human body for
normal carbohydrate and lipid
metabolism (Wilson and Gondy, 1995). A number of diabetes-like signs
and symptoms are seen in
chromium deficiency including impaired glucose tolerance, fasting
hyperglycemia, glucosuria,
elevated circulating insulin and peripheral neuropathy. Dietary
chromium intake less than 25% has been
reported to adversely affect insulin sensitivity in subjects with
mildly impaired glucose tolerance
(Anderson, 2000). Over time, urinary chromium losses may contribute to
insulin resistance and
exacerbate compromised insulin sensitivity in individuals with type 2
diabetes mellitus (T2DM).
(Anderson et al., 1991 ; Cefalu and Hu, 2004)
It has been reported that chromium complexes bind to an oligopeptide
in order to become biologically
active (Davis 1997). The chromium-bound peptide then binds to the
insulin receptor and activates
tyrosine kinase, amplifying insulin action (Cefalu and Hu, 2004; Wang
et al., 2006). In vivo studies have
shown that chromium picolinate stimulates intracellular GLUT-4
transporters to transl